Universities Allied for Essential Medicines is calling for new incentive models for research and development so that new treatments can be found for neglected tropical diseases to fight antibiotic resistance, and is asking that health issues supersede trade interests.

Faced with growing global concern over microbial resistance to antibiotic treatments, the annual World Health Assembly last week adopted a resolution to establish a global action plan on antimicrobial resistance.

The Global Fund to Fight AIDS, Tuberculosis and Malaria has launched an initiative with other agencies aimed at expanding global access to health products such as medicines. But the Fund has had some explaining to do about the initiative, which some say could encompass a plan to allow different prices based on national income levels.

Discussions on access to essential medicines yesterday at the World Health Organization were in some ways overshadowed by the recent leak of a global pharmaceutical campaign aimed at derailing efforts by the South African government to revise its intellectual property policy. WHO Director General Margaret Chan strongly supported South Africa, as did several developing countries, while developed countries remained silent on the subject.

A recent European Union regulation on customs enforcement of intellectual property rights has raised concerns among civil society actors who find that the regulation might not be an improvement over its previous version under which seizure of legal generic medicines in transit occurred a few years ago, leading to a World Trade Organization dispute.

The World Trade Organization committee on intellectual property rights met this week and addressed a request by least developed countries for an extension of the period to enforce WTO intellectual property rules. LDCs want that the extension be extinguishable only after a country ceases to be considered as ‘least developed’, which developing countries largely supported. Developed countries, however, were hesitant about the terms of the proposed extension.

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) held its 26th assembly this week and elected its new president. He presented the future orientation of the industry group, saying will work on trust-building and needs predictability in the regulatory process, policies that sustain and encourage innovation, and a strong intellectual property system, he said.